# A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

> **NCT01610596** · PHASE2 · COMPLETED · sponsor: **Therapeutics, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Psoriasis
- Plaque Psoriasis

## Interventions

- **DRUG:** Halobetasol Propionate Lotion 0.05%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01610596
- **Lead sponsor:** Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610596, "A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01610596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*